Corus to stop distributing Nickelodeon, four other kids' entertainment channels
The company says in a statement it will stop distributing ABC Spark, Nickelodeon, Disney French (La Chaine Disney), Disney XD and Disney Jr. channels as of Sept. 1.
A spokesperson says the move comes after a 'comprehensive review' of Corus' portfolio of channels surrounding the 'evolving needs of our audiences and distribution partners.'
Corus says it will still operate the Disney Channel across its TV and streaming platforms.
Last month, the company said it slashed seven per cent of employee costs in its most recent quarter and was continuing to look for savings amid an advertising revenue slump.
Chief executive John Gossling told analysts that Corus anticipates TV advertising revenue to decline about 20 per cent year-over-year in the current quarter as 'geopolitical and economic uncertainty' linger.
Monday Mornings
The latest local business news and a lookahead to the coming week.
This report by The Canadian Press was first published July 11, 2025.
Companies in this story: (TSX:CJR.B)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025
PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) ('BriaCell' or the 'Company'), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. The titles of the poster presentations are listed below. #8212: Phase III Pivotal Trial of Bria-IMT + CPI vs Physician's Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) #3928: Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC) Abstracts will be published online via the ESMO website at 00:05 CEST on October 13 th 2025 (6:05 pm ET on October 12 th). Following the presentations, copies of the presentations will be posted on About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at Safe Harbor This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell presenting clinical data presentations at the ESMO Congress 2025; and the contents of all such presentations are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 'Risks and Uncertainties' in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under 'Risks and Uncertainties' in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information
Globe and Mail
27 minutes ago
- Globe and Mail
Canopy Growth to Report First Quarter Fiscal 2026 Financial Results on August 8, 2025
Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX:WEED, NASDAQ:CGC) will release its financial results for the first quarter fiscal year 2026 ended June 30, 2025 before financial markets open on August 8, 2025. Following the release of its first quarter fiscal year 2026 financial results, Canopy Growth will host an audio webcast with Luc Mongeau, CEO and Tom Stewart, Interim CFO on August 8, 2025 at 10 AM Eastern Time (ET). Webcast Information A live audio webcast will be available at: Replay Information A replay will be accessible by webcast until 11:59 PM ET on November 6, 2025 at: About Canopy Growth Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc. , a California-based producer of high-quality cannabis extracts and clean vape technology. At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer.
Globe and Mail
27 minutes ago
- Globe and Mail
St. Augustine Closes Private Placement
Singapore, Singapore--(Newsfile Corp. - July 25, 2025) - St. Augustine Gold and Copper Limited (TSX: SAU) (" St. Augustine" or the " Company") is pleased to announce that its previously announced (June 9, 2025) non-brokered private placement financing of 341,038,196 common shares of the Company (the " Shares") has closed at a price of $0.073 per Unit (the " Private Placement") for gross proceeds of up to $24,895,379. The Company intends to use net proceeds of the Private Placement for general corporate purposes including completion of a feasibility study and organizing financing for the Company's King-king copper-gold project. No insiders participated. About St. Augustine St. Augustine (SAU.T) is a TSX-listed mining company focused on the development of the King-king Copper-Gold Project. The Project is one of the largest undeveloped copper-gold deposits in the world and is listed as a top three-priority mining project by the Philippine government. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This announcement includes certain "forward-looking statements" within the meaning of Canadian securities legislation. All statements, other than statements of historical fact included herein are forward looking statements. Forward-looking statements involve various risks and uncertainties and are based on certain factors and assumptions. While we consider these assumptions to be reasonable based on currently available information, they may prove to be incorrect. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking information is also subject to certain factors, including risks and uncertainties, that could cause actual results to differ materially from the Company's current expectations, including changes in market conditions, governmental or regulatory developments and general economic conditions. Other risks and uncertainties related to the Company are disclosed under the heading "Risk Factors" in the Company's Annual Information Form dated March 31, 2025 and filed with Canadian securities regulatory authorities on the SEDAR+ website at Forward-looking information contained in this announcement is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely on this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time except as required by applicable securities law.
